Literature DB >> 29680362

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.

Andrea Necchi1, Daniele Raggi2, Patrizia Giannatempo2, Alessandra Alessi3, Gianluca Serafini3, Maurizio Colecchia4, Siraj M Ali5, Jon H Chung5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29680362     DOI： 10.1016/j.ejca.2018.03.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  2 in total

Review 1.  Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Authors:  Flurina A M Saner; Alan Herschtal; Brad H Nelson; Anna deFazio; Ellen L Goode; Susan J Ramus; Ahwan Pandey; Jessica A Beach; Sian Fereday; Andrew Berchuck; Stephanie Lheureux; Celeste Leigh Pearce; Paul D Pharoah; Malcolm C Pike; Dale W Garsed; David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

2.  Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

Authors:  P Grivas; Y Loriot; R Morales-Barrera; M Y Teo; Y Zakharia; S Feyerabend; N J Vogelzang; E Grande; N Adra; A Alva; A Necchi; A Rodriguez-Vida; S Gupta; D H Josephs; S Srinivas; K Wride; D Thomas; A Simmons; A Loehr; R L Dusek; D Nepert; S Chowdhury
Journal:  BMC Cancer       Date:  2021-05-24       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.